Narhex Life Sciences, an Australian pharma whose main asset was a China joint venture, has declared bankruptcy. In 2006, Narhex and China Shaanxi Dacheng International Trading Co. established a JV to develop a protease inhibitor for HIV. It also had licensed China rights to Cavidi diagnostic products, which could measure HIV viral load. From the start, the goal was to develop the products for use in China. The JV, which was called Xi’an Hex Life Sciences Co., was supported by the Xi’an High Tech Authority. More details...